Leanne J. Kosse

Leanne J. Kosse

Auto-generated profile, based on publicly available information

Leanne J. Kosse

Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Rheumatology
Verified
Journal Article
Closed access
LKLeanne J Kosse
Leanne J Kosse
NJNaomi T Jessurun
Naomi T Jessurun
RHRenske C F Hebing
Renske C F Hebing
VHVictor J B Huiskes
Victor J B Huiskes
KSKarin M Spijkers
Karin M Spijkers
MNMike T Nurmohamed
Mike T Nurmohamed
Objectives: Assessment of the quality of patient-reported medical information in the Dutch Biologic Monitor and evaluation of the representativeness of the sampled participants. Methods: Consecutive adult patients using a biologic DMARD (bDMARD) for an immune-mediated inflammatory disease were included in eight Dutch centres. For this substudy, data of 550 patients with inflammatory rheumatic diseases were used. Patient-reported bDMARD prescription, indication and combination therapy were verified for patients that permitted access to their electronic health record using percentage agreement and/or Cohen’s kappa (n = 483). Conservative post hoc sensitivity analysis was performed to account for missing data. Population representativeness was tested for the entire substudy population by comparing age, gender and prescribed bDMARD to the centres’ reference populations using Mann–Whitney U-test, χ2 goodness-of-fit or Fisher’s exact test with Monte Carlo simulation (n = 550). Results: The correct bDMARD was reported by 95.8% of the participants. Agreement between patients and electronic health record was almost perfect for indications (κ = 0.832) and substantial for combination therapies (κ = 0.725). Agreement on combination therapies remained substantial after post hoc sensitivity analysis (κ = 0.640). Gender distribution (P > 0.05) and bDMARD use (P > 0.05) were similar to the reference populations. Median age was different (58.0 vs 56.0 years, P = 0.04), but considered clinically irrelevant. Conclusion: The Dutch Biologic Monitor seems to be a valid tool to obtain patient-reported medical information. Reported medical information generally corresponded to the electronic health records and the participants represented their reference populations regarding age, gender and prescribed bDMARD.

15 December 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TGTheun de Groot
Theun de Groot
LDLars Damen
Lars Damen
LKLeanne Kosse
Leanne Kosse
MAMohammad Alsady
Mohammad Alsady
RDRosalinda Doty
Rosalinda Doty
PDPeter M T Deen
Peter M T Deen
Glycogen synthase kinase 3 (GSK3) plays an important role in the development of diabetes mellitus and renal injury. GSK3 inhibition increases glucose uptake in insulin-insensitive muscle and adipose tissue, while it reduces albuminuria and glomerulosclerosis in acute kidney injury. The effect of chronic GSK3 inhibition in diabetic nephropathy is not known. We tested the effect of lithium, the only clinical GSK3 inhibitor, on the development of diabetes mellitus and kidney injury in a mouse model of diabetic nephropathy. Twelve-week old female BTBR-ob/ob mice were treated for 12 weeks with 0, 10 and 40 mmol LiCl/kg after which the development of diabetes and diabetic nephropathy were analysed. In comparison to BTBR-WT mice, ob/ob mice demonstrated elevated bodyweight, increased blood glucose/insulin levels, urinary albumin and immunoglobulin G levels, glomerulosclerosis, reduced nephrin abundance and a damaged proximal tubule brush border. The lithium-10 and -40 diets did not affect body weight and resulted in blood lithium levels of respectively <0.25 mM and 0.48 mM. The Li-40 diet fully rescued the elevated non-fasting blood glucose levels. Importantly, glomerular filtration rate was not affected by lithium, while urine albumin and immunoglobulin G content were further elevated. While lithium did not worsen the glomerulosclerosis, proximal tubule function seemed affected by lithium, as urinary NGAL levels were significantly increased. These results demonstrate that lithium attenuates non-fasting blood glucose levels in diabetic mice, but aggravates urinary albumin and immunoglobulin G content, possibly resulting from proximal tubule dysfunction.

24 October 2022 in Expert Opinion on Drug Safety
Verified
Journal Article
Open access
HWHenrike J. Westerink
Henrike J. Westerink
LKLeanne J. Kosse
Leanne J. Kosse
NJNaomi Jessurun
Naomi Jessurun
ATAstrid van Tubergen
Astrid van Tubergen
HVHarald E. Vonkeman
Harald E. Vonkeman
MVMarieke de Vries
Marieke de Vries
Previous studies showed a discrepancy between health-care professionals’ (HCPs’) and patients’ perspective on adverse drug reaction (ADR) burden. However, it is unclear which factors make an ADR bu...

1 March 2023 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
HGHelen Gosselt
Helen Gosselt
JLJette A. van Lint
Jette A. van Lint
LKLeanne J. Kosse
Leanne J. Kosse
PSPhyllis I. Spuls
Phyllis I. Spuls
HVHarald E. Vonkeman
Harald E. Vonkeman
NJNaomi Jessurun
Naomi Jessurun
To examine sex differences in relation to the nature, frequency and burden of patient-reported adverse drug reactions (ADRs) in patients with inflammatory rheumatic diseases.Rheumatoid arthritis, p...

27 January 2023 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
KVKimberly Velthuis
Kimberly Velthuis
NJNaomi Jessurun
Naomi Jessurun
TNThi D.M. Nguyen
Thi D.M. Nguyen
JSJoep Scholl
Joep Scholl
JJJurriaan R.G. Jansen
Jurriaan R.G. Jansen
HVHarald E. Vonkeman
Harald E. Vonkeman
This study aims to compare nature and frequency of adverse drug reactions (ADRs), time to first ADR, drug survival, and the share of ADRs in treatment discontinuation of first-time treatment with a...

26 July 2024 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
JQJanneke M. Quik
Janneke M. Quik
HGHelen Gosselt
Helen Gosselt
JLJette A. van Lint
Jette A. van Lint
LKLeanne J. Kosse
Leanne J. Kosse
Peter ten KloosterPeter ten Klooster
Peter ten Klooster
NJNaomi Jessurun
Naomi Jessurun
We aimed to describe the burden of adverse drug reactions (ADRs) reported by patients participating in the Dutch ADR Monitor using a multifactorial burden measurement instrument. The Dutch ADR Monitor is a cohort event monitoring system that collects information on ADR experiences, including burden. This study includes the initial data (November 2022 until May 2023). Patients were asked if experienced ADRs impacted 7 domains of burden: appearance, medical treatment, daily life, fatigue, physical consequences, mental consequences and the course of ADRs. Burden was scored from 0 to 10 on impacted domains. The distributions of these burden scores were demonstrated in Likert plots. The burden between persistent and recurrent ADRs was compared. 92 patients reported 199 ADRs. Impact on the domains fatigue and daily life were experienced most frequently, except for skin and subcutaneous tissue ADRs, where impact on appearance and mental consequences were experienced most frequently. Fatigue was considered the most burdensome domain. No difference in burden was found between persistent (median = 7, IQR = 4) and recurrent ADRs (median = 6, IQR = 4, p = 0.59). This is the first study investigating burden of ADRs on 7 domains in patients with chronic diseases. Impact on the domain fatigue was considered most burdensome.